Landscapes / Companies
Ascendis Pharma A/S not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
3 approved
2 in Phase 2
Drugs
5
in active trials · 6 in all
Trials
6 active
12 since 2021
Drugs5
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Parathyroid hormone analog |
Approved | Jun 2027Phase 3 trial completes | |||
| Next date | Jun 2027 · Phase 3 trial completes | ||||
| Also tested for | Hypoparathyroidism, Endocrine System Diseases and 1 more | ||||
| Open drug page | |||||
— |
Approved | Sep 2027Phase 2 trial completes | |||
| Next date | Sep 2027 · Phase 2 trial completes | ||||
| Also tested for | Achondroplasia, Hypochondroplasia | ||||
| Open drug page | |||||
Recombinant human growth hormone |
Ascendis Pharma Endocrinology Division A/S |
Approved | Feb 2028Phase 3 trial completes | ||
| Next date | Feb 2028 · Phase 3 trial completes | ||||
| Also tested for | Turner Syndrome, Achondroplasia and 3 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Aug 2027Phase 1/2 trial completes | |||
| Next date | Aug 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Locally Advanced Solid Tumor and 11 more | ||||
| Open drug page | |||||
— |
Ascendis Pharma Oncology Division A/S |
Phase 1/2 | Aug 2027Phase 1/2 trial completes | ||
| Next date | Aug 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Locally Advanced Solid Tumor and 11 more | ||||
| Open drug page | |||||
About
- No active trial
- ACP-001
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021